Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to preliminarily evaluate the efficacy and safety of chemotherapy plus subsequent loco-regional radiotherapy combined with toripalimab for the de novo metastatic nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
DRUG: Chemotherapy plus radiotherapy and Toripalimab
Objective Response Rate, The proportion of patients who achieved an objective response, defined as those with radiologically confirmed complete or partial response according to RECIST 1.1 assessed by the investigator;, 1 year
Disease Control Rate, The proportion of patients who achieved disease control, defined as those with RECIST-defined objective response or stable disease, 1 year|Progression-free survival, The time is defined from the enrolment to RECISTdefined progression or death from any cause, 1 year|The toxicity grade will be assessed according to CTCAE 5.0., Safety profiles, 1 year
This is a single center , single arm, phase II study. All eligible patients with the de novo metastatic NPC are treated with chemotherapy plus subsequent loco-regional radiotherapy combined with toripalimab. The primary objective of this study is to assess objective response rate of chemotherapy plus subsequent loco-regional radiotherapy combined with toripalimab in de novo metastatic nasopharyngeal carcinoma . The secondary objective is to assess progression free survival, and Adverse events.